MedKoo product information:

 Thioguanine

Thioguanine is a synthetic guanosine analogue antimetabolite. Phosphorylated by hypoxanthine-guanine phosphoribosyltransferase, thioguanine incorporates into DNA and RNA, resulting in inhibition of DNA and RNA syntheses and cell death. This agent also inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, thereby inhibiting purine synthesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).Its principal use is in acute leukaemias and chronic myeloid leukaemia. It has been investigated for use in treatment of psoriasis.

Mechanism of Action

After incorporation into DNA, the thiocarbonyl of thioguanine has a tendency to be methylated. This produces a base similar to 6-O-methylguanine. During a second round of replication, the mismatch repair system will recognize the mismatch between the methylated base and cytosine. The attempt to repair such a mismatch is abortive since no nucleotides can be properly matched with the methylated base. This leads to persistent 100-200 base single strand breaks. Such a genotoxic stress will trigger cell cycle arrest and cell death. In this regard, thioguanine and mercaptopurine, although categorized as antimetabolites, exert their functions more like a genotoxic methylating agents, such as temozolomide, which methylates DNA and generate 6-O-methylguanine and cytosine mismatch. The ability of thioguanine and mercaptopurine to trigger genotoxic stress is also exemplified by their treatment-related acute myeloid leukemia (AML), which is uncommon for antimetabolites, but common for alkylating agents and topoisomerase inhibitors. (source: http://en.wikipedia.org/wiki/Thioguanine).

DRUG DESCRIPTION

TABLOID brand Thioguanine was synthesized and developed by Hitchings, Elion, and associates at the Wellcome Research Laboratories. It is one of a large series of purine analogues which interfere with nucleic acid biosynthesis, and has been found active against selected human neoplastic diseases. Thioguanine, known chemically as 2-amino-1,7-dihydro-6H-purine-6-thione, is an analogue of the nucleic acid constituent guanine, and is closely related structurally and functionally to PURINETHOL® (mercaptopurine). TABLOID brand Thioguanine is available in tablets for oral administration. Each scored tablet contains 40 mg thioguanine and the inactive ingredients gum acacia, lactose, magnesium stearate, potato starch, and stearic acid.

CLINICAL PHARMACOLOGY

Clinical studies have shown that the absorption of an oral dose of thioguanine in humans is incomplete and variable, averaging approximately 30% of the administered dose (range: 14% to 46%). Following oral administration of 35S-6-thioguanine, total plasma radioactivity reached a maximum at 8 hours and declined slowly thereafter. Parent drug represented only a very small fraction of the total plasma radioactivity at any time, being virtually undetectable throughout the period of measurements. The oral administration of radiolabeled thioguanine revealed only trace quantities of parent drug in the urine. However, a methylated metabolite, 2-amino-6-methylthiopurine (MTG), appeared very early, rose to a maximum 6 to 8 hours after drug administration, and was still being excreted after 12 to 22 hours. Radiolabeled sulfate appeared somewhat later than MTG but was the principal metabolite after 8 hours. Thiouric acid and some unidentified products were found in the urine in small amounts. Intravenous administration of 35S-6-thioguanine disclosed a median plasma half-disappearance time of 80 minutes (range: 25 to 240 minutes) when the compound was given in single doses of 65 to 300 mg/m2. Although initial plasma levels of thioguanine did correlate with the dose level, there was no correlation between the plasma half-disappearance time and the dose.

Thioguanine is incorporated into the DNA and the RNA of human bone marrow cells. Studies with intravenous 35S-6-thioguanine have shown that the amount of thioguanine incorporated into nucleic acids is more than 100 times higher after 5 daily doses than after a single dose. With the 5-dose schedule, from one-half to virtually all of the guanine in the residual DNA was replaced by thioguanine. Tissue distribution studies of 35S-6-thioguanine in mice showed only traces of radioactivity in brain after oral administration. No measurements have been made of thioguanine concentrations in human cerebrospinal fluid (CSF), but observations on tissue distribution in animals, together with the lack of CNS penetration by the closely related compound, mercaptopurine, suggest that thioguanine does not reach therapeutic concentrations in the CSF. Monitoring of plasma levels of thioguanine during therapy is of questionable value. There is technical difficulty in determining plasma concentrations, which are seldom greater than 1 to 2 mcg/mL after a therapeutic oral dose. More significantly, thioguanine enters rapidly into the anabolic and catabolic pathways for purines, and the active intracellular metabolites have appreciably longer half-lives than the parent drug. The biochemical effects of a single dose of thioguanine are evident long after the parent drug has disappeared from plasma. Because of this rapid metabolism of thioguanine to active intracellular derivatives, hemodialysis would not be expected to appreciably reduce toxicity of the drug.

Thioguanine competes with hypoxanthine and guanine for the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) and is itself converted to 6-thioguanylic acid (TGMP). This nucleotide reaches high intracellular concentrations at therapeutic doses. TGMP interferes at several points with the synthesis of guanine nucleotides. It inhibits de novo purine biosynthesis by pseudo-feedback inhibition of glutamine-5-phosphoribosylpyrophosphate amidotransferase-the first enzyme unique to the de novo pathway for purine ribonucleotide synthesis. TGMP also inhibits the conversion of inosinic acid (IMP) to xanthylic acid (XMP) by competition for the enzyme IMP dehydrogenase. At one time TGMP was felt to be a significant inhibitor of ATP:GMP phosphotransferase (guanylate kinase), but recent results have shown this not to be so. Thioguanylic acid is further converted to the di- and tri-phosphates, thioguanosine diphosphate (TGDP) and thioguanosine triphosphate (TGTP) (as well as their 2' -deoxyribosyl analogues) by the same enzymes which metabolize guanine nucleotides. Thioguanine nucleotides are incorporated into both the RNA and the DNA by phosphodiester linkages and it has been argued that incorporation of such fraudulent bases contributes to the cytotoxicity of thioguanine.

Thus, thioguanine has multiple metabolic effects and at present it is not possible to designate one major site of action. Its tumor inhibitory properties may be due to one or more of its effects on (a) feedback inhibition of de novo purine synthesis; (b) inhibition of purine nucleotide interconversions; or (c) incorporation into the DNA and the RNA. The net consequence of its actions is a sequential blockade of the synthesis and utilization of the purine nucleotides. The catabolism of thioguanine and its metabolites is complex and shows significant differences between humans and the mouse. In both humans and mice, after oral administration of 35S-6-thioguanine, urine contains virtually no detectable intact thioguanine. While deamination and subsequent oxidation to thiouric acid occurs only to a small extent in humans, it is the main pathway in mice. The product of deamination by guanase, 6-thioxanthine is inactive, having negligible antitumor activity. This pathway of thioguanine inactivation is not dependent on the action of xanthine oxidase, and an inhibitor of that enzyme (such as allopurinol) will not block the detoxification of thioguanine even though the inactive 6-thioxanthine is normally further oxidized by xanthine oxidase to thiouric acid before it is eliminated. In humans, methylation of thioguanine is much more extensive than in the mouse. The product of methylation, 2-amino-6-methylthiopurine, is also substantially less active and less toxic than thioguanine and its formation is likewise unaffected by the presence of allopurinol. Appreciable amounts of inorganic sulfate are also found in both murine and human urine, presumably arising from further metabolism of the methylated derivatives.

In some animal tumors, resistance to the effect of thioguanine correlates with the loss of HGPRTase activity and the resulting inability to convert thioguanine to thioguanylic acid. However, other resistance mechanisms, such as increased catabolism of TGMP by a nonspecific phosphatase, may be operative. Although not invariable, it is usual to find cross-resistance between thioguanine and its close analogue, PURINETHOL (mercaptopurine).

  1: Ren X, Xu YZ, Karran P. Photo-oxidation of 6-Thioguanine by UVA: The Formation of Addition Products with Low Molecular Weight Thiol Compounds. Photochem Photobiol. 2010 Jun 21. [Epub ahead of print] PubMed PMID: 20573042.

2: Ren X, Li F, Jeffs G, Zhang X, Xu YZ, Karran P. Guanine sulphinate is a major stable product of photochemical oxidation of DNA 6-thioguanine by UVA irradiation. Nucleic Acids Res. 2010 Apr;38(6):1832-40. Epub 2009 Dec 21. PubMed PMID: 20026585; PubMed Central PMCID: PMC2847230.

3: Brem R, Li F, Karran P. Reactive oxygen species generated by thiopurine/UVA cause irreparable transcription-blocking DNA lesions. Nucleic Acids Res. 2009 Apr;37(6):1951-61. Epub 2009 Feb 10. PubMed PMID: 19208641; PubMed Central PMCID: PMC2665240.

4: Hawwa AF, Millership JS, Collier PS, Vandenbroeck K, McCarthy A, Dempsey S, Cairns C, Collins J, Rodgers C, McElnay JC. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol. 2008 Oct;66(4):517-28. Epub 2008 Jun 28. PubMed PMID: 18662289; PubMed Central PMCID: PMC2561120.

5: Vethe NT, Bremer S, Bergan S. IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine. Scand J Clin Lab Invest. 2008;68(4):277-85. PubMed PMID: 18609073.

6: Krishnamurthy P, Schwab M, Takenaka K, Nachagari D, Morgan J, Leslie M, Du W, Boyd K, Cheok M, Nakauchi H, Marzolini C, Kim RB, Poonkuzhali B, Schuetz E, Evans W, Relling M, Schuetz JD. Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res. 2008 Jul 1;68(13):4983-9. PubMed PMID: 18593894.

7: Yuan B, Wang Y. Mutagenic and cytotoxic properties of 6-thioguanine, S6-methylthioguanine, and guanine-S6-sulfonic acid. J Biol Chem. 2008 Aug 29;283(35):23665-70. Epub 2008 Jun 30. PubMed PMID: 18591241.

8: Zeng X, Kinsella TJ. Mammalian target of rapamycin and S6 kinase 1 positively regulate 6-thioguanine-induced autophagy. Cancer Res. 2008 Apr 1;68(7):2384-90. PubMed PMID: 18381446.

9: Saczewski F, Maruszak M, Bednarski PJ. Synthesis and cytotoxic activity of imidazo[1,2-a]-1,3,5-triazine analogues of 6-mercaptopurine. Arch Pharm (Weinheim). 2008 Feb;341(2):121-5. PubMed PMID: 18186543.

10: Kalra S, Jena G, Tikoo K, Mukhopadhyay AK. Preferential inhibition of xanthine oxidase by 2-amino-6-hydroxy-8-mercaptopurine and 2-amino-6-purine thiol. BMC Biochem. 2007 May 18;8:8. PubMed PMID: 17511860; PubMed Central PMCID: PMC1885804.

11: Mladosievicova B, Carter A, Kristova V. Genetic tests for predicting the toxicity and efficacy of anticancer chemotherapy. Neoplasma. 2007;54(3):181-8. Review. PubMed PMID: 17447847.

12: Eklund BI, Gunnarsdottir S, Elfarra AA, Mannervik B. Human glutathione transferases catalyzing the bioactivation of anticancer thiopurine prodrugs. Biochem Pharmacol. 2007 Jun 1;73(11):1829-41. Epub 2007 Feb 12. PubMed PMID: 17433263.

13: Tan TM, Yang F, Fu H, Raghavendra MS, Lam Y. Traceless solid-phase synthesis and biological evaluation of purine analogs as inhibitors of multidrug resistance protein 4. J Comb Chem. 2007 Mar-Apr;9(2):210-8. PubMed PMID: 17348727.

14: Nagai K, Nagasawa K, Kihara Y, Okuda H, Fujimoto S. Anticancer nucleobase analogues 6-mercaptopurine and 6-thioguanine are novel substrates for equilibrative nucleoside transporter 2. Int J Pharm. 2007 Mar 21;333(1-2):56-61. Epub 2006 Sep 29. PubMed PMID: 17088032.

15: Choi S, Choi HH, Choi JH, Yoon BH, You HJ, Hyun JW, Kim JE, Ye SK, Chung MH. Inhibitory effect of 8-oxo-7,8-dihydro-2'-deoxyguanosine on the growth of KG-1 myelosarcoma in Balb/c nude mice. Leuk Res. 2006 Nov;30(11):1425-36. Epub 2006 May 5. PubMed PMID: 16678259.

16: Sawada K, Noda K, Nakajima H, Shimbara N, Furuichi Y, Sugimoto M. Differential cytotoxicity of anticancer agents in pre- and post-immortal lymphoblastoid cell lines. Biol Pharm Bull. 2005 Jul;28(7):1202-7. PubMed PMID: 15997098.

17: Hoffmann M, Chrzanowska M, Hermann T, Rychlewski J. Modeling of purine derivatives transport across cell membranes based on their partition coefficient determination and quantum chemical calculations. J Med Chem. 2005 Jun 30;48(13):4482-6. PubMed PMID: 15974600.

18: Parker WB, Secrist JA 3rd, Waud WR. Purine nucleoside antimetabolites in development for the treatment of cancer. Curr Opin Investig Drugs. 2004 Jun;5(6):592-6. Review. PubMed PMID: 15242246.

19: Rooseboom M, Commandeur JN, Vermeulen NP. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev. 2004 Mar;56(1):53-102. Review. PubMed PMID: 15001663.

20: Gunnarsdottir S, Elfarra AA. Cytotoxicity of the novel glutathione-activated thiopurine prodrugs cis-AVTP [cis-6-(2-acetylvinylthio)purine] and trans-AVTG [trans-6-(2-acetylvinylthio)guanine] results from the National Cancer Institute's anticancer drug screen. Drug Metab Dispos. 2004 Mar;32(3):321-7. PubMed PMID: 14977866.

21: Furusawa E, Hirazumi A, Story S, Jensen J. Antitumour potential of a polysaccharide-rich substance from the fruit juice of Morinda citrifolia (Noni) on sarcoma 180 ascites tumour in mice. Phytother Res. 2003 Dec;17(10):1158-64. PubMed PMID: 14669249.

22: Kaaijk P, Kaspers GJ, Van Wering ER, Broekema GJ, Loonen AH, Hählen K, Schmiegelow K, Janka-Schaub GE, Henze G, Creutzig U, Veerman AJ. Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia. Br J Cancer. 2003 Mar 10;88(5):775-81. PubMed PMID: 12618889; PubMed Central PMCID: PMC2376358.

23: Bohon J, de los Santos CR. Structural effect of the anticancer agent 6-thioguanine on duplex DNA. Nucleic Acids Res. 2003 Feb 15;31(4):1331-8. PubMed PMID: 12582253; PubMed Central PMCID: PMC150222.

24: Krynetski EY, Krynetskaia NF, Bianchi ME, Evans WE. A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Res. 2003 Jan 1;63(1):100-6. PubMed PMID: 12517784.

25: Wielinga PR, Reid G, Challa EE, van der Heijden I, van Deemter L, de Haas M, Mol C, Kuil AJ, Groeneveld E, Schuetz JD, Brouwer C, De Abreu RA, Wijnholds J, Beijnen JH, Borst P. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol. 2002 Dec;62(6):1321-31. PubMed PMID: 12435799.

26: Karran P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis. 2001 Dec;22(12):1931-7. PubMed PMID: 11751422.

27: Pepponi R, Graziani G, Falcinelli S, Vernole P, Levati L, Lacal PM, Pagani E, Bonmassar E, Jiricny J, D'Atri S. hMSH3 overexpression and cellular response to cytotoxic anticancer agents. Carcinogenesis. 2001 Aug;22(8):1131-7. PubMed PMID: 11470740.

28: Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem. 2001 Sep 7;276(36):33747-54. Epub 2001 Jul 10. PubMed PMID: 11447229.

29: Krynetskaia NF, Cai X, Nitiss JL, Krynetski EY, Relling MV. Thioguanine substitution alters DNA cleavage mediated by topoisomerase II. FASEB J. 2000 Nov;14(14):2339-44. PubMed PMID: 11053256.

30: Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clercq E, Balzarini J, Borst P. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7476-81. PubMed PMID: 10840050; PubMed Central PMCID: PMC16570.

31: Krynetskaia NF, Krynetski EY, Evans WE. Human RNase H-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA. Mol Pharmacol. 1999 Oct;56(4):841-8. PubMed PMID: 10496969.

32: Duyn AE, Kaspers GJ, Pieters R, Van Zantwijk CH, Broekema GJ, Hählen K, Veerman AJ. Effects of interleukin 3, interleukin 7, and B-cell growth factor on proliferation and drug resistance in vitro in childhood acute lymphoblastic leukemia. Ann Hematol. 1999 Apr;78(4):163-71. PubMed PMID: 10348147.

33: Chen T, Aidoo A, Mittelstaedt RA, Casciano DA, Heflich RH. Hprt mutant frequency and molecular analysis of Hprt mutations in Fischer 344 rats treated with thiotepa. Carcinogenesis. 1999 Feb;20(2):269-77. PubMed PMID: 10069464.

34: Shi RZ, Lyons SD, Christopherson RI. Metabolic effects of thiopurine derivatives against human CCRF-CEM leukaemia cells. Int J Biochem Cell Biol. 1998 Aug;30(8):885-95. PubMed PMID: 9744080.

35: Aubrecht J, Goad ME, Schiestl RH. Tissue specific toxicities of the anticancer drug 6-thioguanine is dependent on the Hprt status in transgenic mice. J Pharmacol Exp Ther. 1997 Aug;282(2):1102-8. PubMed PMID: 9262380.

36: Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG, Anthoney DA. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene. 1997 Jul 3;15(1):45-52. PubMed PMID: 9233776.

37: Tamiya T, Ono Y, Wei MX, Mroz PJ, Moolten FL, Chiocca EA. Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine or 6-thioguanine. Cancer Gene Ther. 1996 May-Jun;3(3):155-62. PubMed PMID: 8725879.

38: Coustan-Smith E, Kitanaka A, Pui CH, McNinch L, Evans WE, Raimondi SC, Behm FG, Aricò M, Campana D. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood. 1996 Feb 1;87(3):1140-6. PubMed PMID: 8562940.

39: Pályi I, Turi G, Hullán L, Szikla K, Bak M. Dominant expression of multidrug resistance in intraspecific murine lymphoma hybrid cells. Cancer Chemother Pharmacol. 1994;34(1):81-5. PubMed PMID: 7909724.

40: Warren DJ, Slørdal L. A high-performance liquid chromatographic method for the determination of 6-thioguanine residues in DNA using precolumn derivatization and fluorescence detection. Anal Biochem. 1993 Dec;215(2):278-83. PubMed PMID: 8122790.

41: Nakamura T, Ueda T, Uchida M. [Clinical pharmacology of anticancer agents [Part 5] Antimetabolites (2)]. Gan To Kagaku Ryoho. 1992 Mar;19(3):409-20. Review. Japanese. PubMed PMID: 1543370.

42: Ferguson LR, Hill CL, Morecombe P. Induction of resistance to 6-thioguanine and cytarabine by a range of anticancer drugs in Chinese hamster AA8 cells. Eur J Cancer. 1992;28A(4-5):736-42. PubMed PMID: 1381928.

43: Priebe TS, Atkinson EN, Pan BF, Nelson JA. Intrinsic resistance to anticancer agents in the murine pancreatic adenocarcinoma PANC02. Cancer Chemother Pharmacol. 1992;29(6):485-9. PubMed PMID: 1348974.

44: Tan YY, Epstein LB, Armstrong RD. In vitro evaluation of 6-thioguanine and alpha-interferon as a therapeutic combination in HL-60 and natural killer cells. Cancer Res. 1989 Aug 15;49(16):4431-4. PubMed PMID: 2743331.

45: Pályi I, Bence J, Szikla K, Hullán L. Dominance of resistance to the alkylating agent 1,2:5,6-dianhydrogalactitol in P388 mouse lymphoma hybrid cells. Cancer Chemother Pharmacol. 1989;23(1):41-6. PubMed PMID: 2909289.

46: Hassan HT, Rees JK. Low concentrations of cytosine arabinoside, 6-thioguanine, actinomycin-D and aclacinomycin A stimulates the differentiation of normal human marrow myeloid progenitor cells. Med Oncol Tumor Pharmacother. 1989;6(3):213-7. PubMed PMID: 2615525.

47: Gupta RS, Murray W, Gupta R. Cross resistance pattern towards anticancer drugs of a human carcinoma multidrug-resistant cell line. Br J Cancer. 1988 Oct;58(4):441-7. PubMed PMID: 3207599; PubMed Central PMCID: PMC2246790.

48: Gupta RS, Bromke A, Bryant DW, Gupta R, Singh B, McCalla DR. Etoposide (VP16) and teniposide (VM26): novel anticancer drugs, strongly mutagenic in mammalian but not prokaryotic test systems. Mutagenesis. 1987 May;2(3):179-86. PubMed PMID: 3325741.

49: Rose WC, Huftalen JB, Bradner WT, Schurig JE. In vivo characterization of P388 leukemia resistant to mitomycin C. In Vivo. 1987 Jan-Feb;1(1):47-52. PubMed PMID: 2979764.

50: Furusawa E, Furusawa S. Therapeutic potentials of pretazettine, standard anticancer drugs, and combinations on subcutaneously implanted Lewis lung carcinoma. Chemotherapy. 1986;32(6):521-9. PubMed PMID: 3802955.

51: Levin VA. Chemotherapy of primary brain tumors. Neurol Clin. 1985 Nov;3(4):855-66. Review. PubMed PMID: 3001491.

52: Singh B, Gupta RS. Species-specific differences in the toxicity and mutagenicity of the anticancer drugs mithramycin, chromomycin A3, and olivomycin. Cancer Res. 1985 Jun;45(6):2813-20. PubMed PMID: 3157449.

53: Gupta RS. Cross-resistance of vinblastine- and taxol-resistant mutants of Chinese hamster ovary cells to other anticancer drugs. Cancer Treat Rep. 1985 May;69(5):515-21. PubMed PMID: 2860971.

54: Schwarzmeier JD, Paietta E, Mittermayer K, Pirker R. Prediction of the response to chemotherapy in acute leukemia by a short-term test in vitro. Cancer. 1984 Feb 1;53(3):390-5. PubMed PMID: 6692253.

55: Wiseman A, Kramer DL, Porter CW. Isolation and uptake characteristics of human cell variants resistant to the antiproliferative effects of methylglyoxal bis(guanylhydrazone). Cancer Res. 1983 Dec;43(12 Pt 1):5937-42. PubMed PMID: 6315222.

56: Singh B, Gupta RS. Mutagenic responses of thirteen anticancer drugs on mutation induction at multiple genetic loci and on sister chromatid exchanges in Chinese hamster ovary cells. Cancer Res. 1983 Feb;43(2):577-84. PubMed PMID: 6848181.

57: Singh B, Gupta RS. Comparison of the mutagenic responses of 12 anticancer drugs at the hypoxanthine-guanine phosphoribosyl transferase and adenosine kinase loci in Chinese hamster ovary cells. Environ Mutagen. 1983;5(6):871-80. PubMed PMID: 6317371.

58: Loo TL, Lu K, Benvenuto JA, Rosenblum MG. Disposition and metabolism of thiopurines III. beta-2'-Deoxythioguanosine and 6-thioguanine in the dog. Cancer Chemother Pharmacol. 1981;6(2):131-6. PubMed PMID: 7307231.

59: Mehta BM, Meyers MB, Hutchison DJ. Microbiologic assay for cytosine arabinoside (NSC-63878): the use of a mutant of streptococcus faecium var. durans resistant to methotrexate (NSC-740) and 6-mercaptopurine (NSC-755). Cancer Chemother Rep. 1975 May-Jun;59(3):515-22. PubMed PMID: 1203881.

60: Horton J, Mittelman A, Taylor SG 3rd, Jurkowitz L, Bennett JM, Ezdinli E, Colsky J, Hanley JA. Phase II trials with procarbazine (NSC-77213), streptozotocin (NSC-85998), 6-THIOGUANINE (NSC-752), and CCNU (NSC-79037) in patients with metastatic cancer of the large bowel. Cancer Chemother Rep. 1975 Mar-Apr;59(2 Pt 1):333-40. PubMed PMID: 125147.